Together with prior studies showing the ability of MSC to modulate MyoD activity at overlapping sites at specific promoters, these results suggest a broad potential for MSC to modulate the activity of MyoD, and perhaps other bHLH proteins, during normal development and in cancers. The gene discussed is MYOD1; the disease is cancer.